



RHS Limited ACN 010 126 708

ASX Release  
9<sup>th</sup> June 2017

## Information Required under ASX Listing Rule 3.10.5A

**Adelaide, 9 June 2017:** RHS Limited (ASX: RHS) ("RHS" or "the Company") provides the following information required under ASX Listing Rule 3.10.5A:

- a. Dilution to existing holders:  
The dilutive effect, of the 7.1A placement of 7,920,619 Shares, on existing shareholders not participating in the placement, is 8.8%.

Further details of the approximate percentage of the issued capital post the placement, held by pre-placement shareholders and new shareholders are as follows.

Shareholder category	Holding pre placement	Holding post placement
Pre-placement security holders who did not participate in the placement	96.8%	88.0%
Pre-placement security holders who did participate in the placement	3.2%	3.6%
Participants in the placement who were not previously security holders		8.4%
Total	100.0%	100.0%

These calculations were made prior to the placement of a further 2,793,666 shares utilising Listing Rule 7.1 capacity.

- b. The company has resolved to utilise the capacity available to it under ASX Listing Rule 7.1A, as it considers this to be the most effective and expedient method for raising funds to meet working capital requirements, whilst preserving remaining capacity under listing rule 7.1.
- c. No underwriting arrangements were in place for the placement, and
- d. Fees incurred in connection with the 7.1A issue were \$66,533.

**Reproductive Health Science Ltd.**  
ACN 010 126 708  
ASX: RHS

**Issued Capital**  
79.2 million shares  
6.9 million options

**Registered Office**  
Level One, BioSA Incubator,  
40-46 West Thebarton Road,  
Thebarton, SA 5031

**Tel:** +61 8 8152 9380  
**Fax:** +61 8 8152 9474

**WEB** [www.rhsc.com.au](http://www.rhsc.com.au)

**Directors**  
Dr David Brookes (Chairman)  
Sue MacLeman  
Johnathon Matthews  
Dr Michelle Fraser (CEO)

**Finance Officer  
& Company Secretary**  
Raymond Ridge

**For further information please contact:**

**Dr Michelle Fraser**  
CEO and Managing Director  
Tel: (+61 8) 8152 9348  
[michelle.fraser@rhsc.com.au](mailto:michelle.fraser@rhsc.com.au)

**Dr David Brookes**  
Chairman  
Tel: (+61 8) 8152 9383  
[david.brookes@rhsc.com.au](mailto:david.brookes@rhsc.com.au)

## **About RHS**

RHS is a developer of advanced single cell genomic technologies focussed on improving health and research outcomes, with over 10 years of technical experience in the field. RHS' platform whole genome amplification (WGA) kit DOPlify™ has been independently verified as globally competitive and is broadly applicable for DNA analysis; it also forms the basis for the Company's EmbryoCollect™ kit that has been specifically developed for Pre-implantation Genetic Screening (PGS). RHS also utilises these technologies, and in-house expertise, to provide both microarray and Next Generation Sequencing PGS services.

**Reproductive Health Science Ltd.**  
ACN 010 126 708  
ASX: RHS

**Issued Capital**  
79.2 million shares  
6.9 million options

**Registered Office**  
Level One, BioSA Incubator,  
40-46 West Thebarton Road,  
Thebarton, SA 5031

**Tel:** +61 8 8152 9380  
**Fax:** +61 8 8152 9474

**WEB** [www.rhsc.com.au](http://www.rhsc.com.au)

**Directors**  
Dr David Brookes (Chairman)  
Sue MacLeman  
Johnathon Matthews  
Dr Michelle Fraser (CEO)

**Finance Officer  
& Company Secretary**  
Raymond Ridge